PhorMed
Growth Stage
Unlocking Biotech Potential with Cellular Restoration
Overview
Platform
Dealmaker Securities
Start Date
10/27/2023
Close Date
01/31/2024
Min. Goal
$10,000
Max. Goal
$5,000,000
Min. Investment
$500
Security Type
Equity - Common
Series
Series A
SEC Filing Type
RegCF
Price Per Share
$1.00
Pre-Money Valuation
$52,523,767
Year Founded
2019
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B2C
Margin
Medium
Capital Intensity
High
PhorMed, with a valuation of $52.5 million, is raising funds on Dealmaker Securities. It is a biopharmaceutical company that is changing the face of genomic medicine. PhorMed uses gene therapy to target and treat cancer cells and mutated cells and is developing a treatment for patients suffering from Hodgkin’s Lymphoma, Parkinson’s Disease, and Acute Myeloid Leukemia. PhorMed uses a leading technology, RP-323, as its gene repair therapy. The drug has completed Phase 1 of the clinical study with positive outcomes and is in Phase 2 now. Ben Chang founded PhorMed in May 2019. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, operations, research and development, general overhead expenses, and company employment.
Summary Profit and Loss Statement
| FY 2022 | FY 2021 | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$1,477,413 |
$573,854 |
Summary Balance Sheet
| FY 2022 | FY 2021 | |
|---|---|---|
|
Cash |
$171,333 |
$105,694 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$746,059 |
$183,724 |
|
Short-Term Debt |
$714,494 |
$227,264 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$714,494 |
$227,264 |
Financials as of: 10/27/2023
Create a free account today to gain access to KingsCrowd analytics.
Raise History
| Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
|---|---|---|---|---|---|---|---|
| PhorMed | 01/31/2024 | Dealmaker Securities | $52,523,767 | - | Equity - Common | Active | RegCF |
| PhorMed | 08/17/2022 | StartEngine | $51,647,023 | $243,864 | Equity - Common | Funded | RegCF |
| PhorMed | 03/25/2022 | StartEngine | $39,000,000 | $2,450,528 | Equity - Common | Funded | RegCF |
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.